Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Heterozygous Familial Hypercholesterolemia Patients Undergoing Lipid Apheresis
2014-001917-20Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Alirocumab with Placebo (2 arms). Started Nov 2014; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2014-001917-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001917-20.